



Author Index
Volume 59
January-June 1999

- Affandi, B., 167
Ajani, U., 181
Akers, R., 195
Alvarez, F., 245, 311
Amer, N.A., 395
Anjalika, 67
Archer, D.F., 175
Astley, S.J., 153
Athayde, C., 115
Aydemir, V., 389
- Ba, M.G., 377
Bajaj, J.S., 333
Baker, J.M., 175
Barbosa, I., 115
Bilekli, C., 389
Blackwell, R., 195
Blanchard, K., 209
Blumenthal, P.D., 245
Bonacho, I., 233
Bozkaya, H., 389
Brache, V., 245, 311
Burkhart, M.C., 271
- Cabezas, E., 219
Camacho-Arroyo, I., 339
Carbonell, J.L.L., 11, 219
Cerbón, M.A., 339
Chai, D., 131
Chapin, R.E., 203
Chen, C., 319
Chen, J., 85
Coccheri, S., 293
Cochon, L., 245
Coelingh Bennink, H.J.T., 167
Colli, E., 227
Connell, E.B., 75
Coutinho, E.M., 115
Coyaji, K., 107
Creinin, M.D., 11, 383
- Dantas, C., 115
Darney, P., 305
Dau, B., 377
Davis, A., 395
D'Cruz, O.J., 319
Delaney, J.C., 203
DelConte, A., 187
Denny, L., 363
den Tonkelaar, I., 357
DeSoto, K.R., 175
Development, S.P.R., 31
- Dhar, J.D., 401
Diadhiou, F., 377
Dieben, T.O.M., 59
Dunson, R., 377
Dunson, T.R., 245
Dwivedi, A.K., 401
- Egarter, C., 287
Eisinger, S.H., 1
El Houssinie, M., 369
Ellertson, C., 107, 147, 209
El Nahal, N., 369
Elul, B., 107
Esteve, J.L.L.C., 11, 219
- Fan, S., 25
Faundes, A., 245
Fauser, B.C.J.M., 237
Flamigni, C., 293
Fonck, K., 253
Franks, P., 1
Frascaro, M., 293
Fraser, I.S., 123, 305, 311
Fuschini, G., 293
- Gammi, L., 293
Ganguly, N.K., 67
García, G.A., 339
Gentzschein, E., 17
Geurts, T.B.P., 167
Gharaibeh, M.N., 395
Gichangi, P.B., 253
Glasier, A., 71
Godwin, A., 161
Gola, G., 293
Gómez-Besteiro, M.I., 233
Gore, B.Z., 1
Grubb, G.S., 187
Gupta, G., 401
Gupta, I., 67
Gupta, S.K., 67
- Hammond, K., 195
Hassan, E.O., 369
Hennekens, C.H., 181
Hess, T., 271
Hickey, M., 123
Hirsch, C., 115
Ho, S.C., 85
Hortin, G., 195
Huber, J., 287
- Imhof, M., 287
Isokoski, M., 257
- Jackanicz, T.M., 305
Jaisamrarn, U., 301
Jensen, J.T., 153
Jeyaraj, D.A., 333
Jick, H., 79
Jick, S.S., 79
Jones, K.P., 175
- Karanja, J.G., 253
Katz, D.F., 91
Kaunitz, A.M., 295
Kigonda, C.S., 253
Kirkkola, A., 257
Korver, T., 167
Kouedou, D., 377
Kuhn, L., 363
- Lacarra, M., 305, 311
Lawson, L., 195
Legnani, C., 293
Li, B., 25
Lippman, J., 161
Loffer, F., 187
Lohiya, N.K., 137
LONG, 31
Lotufo, P.A., 181
Lowrance, J.L., 47
- Macaluso, M., 195
Maikhuri, J.P., 401
Makokha, A., 131
Manivannan, B., 137
Manson, J.A.E., 181
Markham, R., 123
Massaro, J., 161
Mattila, K., 257
Mazariegos, L., 271
Mendoza-Rodriguez, C.A., 339
Miller, W.C., 97
Mishell, D.R., Jr, 5S, 17, 21S, 305
Mishell, D.R., Jr., 311
Mishra, P.K., 137
Moreau, J.C., 377
Morgan, E., 153
Morrison, C.S., 97
Mwethera, P.G., 131

- Nash, H.A., 311
 Nichols, M.D., 153
 Niruthisard, S., 63
- Oddens, B.J., 277, 357
 Okuda, H., 203
 Oral Contraceptive and Hemostasis Study Group, 345
 Owen, D.H., 91
 Özeren, M., 389
- Palareti, G., 293
 Parazzini, F., 227
 Penhallegon, R., 227
 Pita, S., 233
 Ploszaj, S., 17
 Pollack, A.E., 363
 Poppema, S., 1
 Pymar, H.C., 383
- Qian, D., 17
- Rajalakshmi, M., 333
 Reinprayoon, D., 63, 301
 Ridker, P.M., 181
 Rodríguez, G., 147
 Roumen, F.J.M.E., 59
 Russell, P., 123
- Salazar, S., 271
 Salhab, A.S., 395
 Sánchez, C., 219
 Schaff, E.A., 1
- Schwartz, J.L., 11, 383
 Sekadde-Kigonde, C., 97
 Setty, B.S., 401
 Sharma, R.S., 333
 Shomaf, M.S., 395
 Simbar, M., 123
 Sinei, S.K., 97
 Siu, C., 161
 Smith, S.R., 47
 Sokal, D., 377
 Sokol, R.Z., 203
 Spelsberg, A., 181
 Stadalius, L.S., 1
 Stanczyk, F.Z., 17, 203
 Sulak, P., 161
 Sulak, P.J., 35S
 Suwajanakon, S., 63
- Tanda, R., 11, 219
 Taneepanichskul, S., 63, 301
 Tang, G., 25
 Tang, O.S., 25
 Temmerman, M., 253
 Tessarotto, L.A.B., 47
 Tong, D., 227
 Topcuoglu, M.A., 287
 Trussell, J., 147
 Tyagi, A., 333
 Tyrer, L.B., 11S
- Uckun, F.M., 319
 United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)/World Health Organization (WHO)/World Bank (WB), Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation, 31
- Valappil, T., 195
 van Heusden, A.M., 237
 Varela, L., 11, 219
 Vasilakis, C., 79
 Velazco, A., 219
 Virjo, I., 257
- Waurzyniak, B., 319
 Weaver, K., 71
 Weiner, D.H., 97
 Weisberg, E., 305, 311
 Westhoff, C.L., 5S, 25S
 Wiebe, E.R., 7, 265
 Winikoff, B., 107, 209
 Wolfe, G.W., 203
 Wright, T.C., 363
 Wysocki, S., 39S
- Yip, P., 25
 Yiv, S.H., 319
 Young, L., 123
- Zhu, Z., 319

Subject Index Volume 59 January-June 1999

- Acceptability,
 - Cyclofem®, 383
 - Mesigyna®, 383
 - nonmedicated vaginal ring, 59
- Activated protein C resistance screening, before OC treatment, 293
- Anti-HIV activity, WHI-05, 319
- Antibiotics, interaction with OC pill, 71
- Benefits, OC use, 39S
- Birth control, women's satisfaction, 277
- Bleeding patterns, use of ethinyl estradiol + norethindrone acetate, CVR, 311
- Blood pressure,
 - effect of DMPA, 301
 - effect of TCu 380A, 301
- Bone mineral density, effect of DMPA, 25
- Breast cancer risk, OC use, 25S
- Breastfeeding, effect of elcometrine, 115
- c-fos* mRNA content, effect of
 - norethisterone/metabolites (rat), 339
- Carbohydrate metabolism, effect of testosterone enanthate (monkey), 333
- Cardiovascular disease risk, effect of vasectomy, 181
- Cardiovascular risks, OC use, 21S
- Castor bean extract,
 - effect on implantation (rabbit), 401
 - effect on ovulation (rabbit), 401
- CDRI 84/35, effect on daily sperm production (rat), 401
- Cervical epithelium, effect of DMPA, 363
- Climacteric women,
 - contraceptive status, 85
 - sexual function, 85
- Clinical evaluation, Norplant implants, 389
- Clinical study,
 - ethinyl estradiol + norethindrone acetate, 161
 - ethinyl estradiol + norethindrone acetate CVR, 305, 311
 - Implanon implant, 167
 - Norplant implants, 389
 - triphasic ethinyl estradiol + norgestimate, 161
- Clinician/patient interaction, OC use, 39S
- Comparative study protocol, OC and hemostasis, 377
- Condom failure, prostrate-specific antigen level in vagina fluid, 195
- Condoms,
 - optical testing, 47
 - women's satisfaction, 277
- Contraception in the prepill era, 75
- Contraceptive discontinuations, 227
- Contraceptive methods, knowledge sources, 257
- Contraceptive status, climacteric women, 85
- Contraceptive vaginal ring (CVR), releasing ethinyl estradiol + norethindrone acetate, 305, 311
- Copper IUD users,
 - level of reactive nitrogen intermediates, 67
 - level of reactive oxygen intermediates, 67
- Copper IUDs, effect on lipid metabolism, 31
- Cu-Fix IUD, effect on endometrium, 63
- Current use and attitudes, oral contraception, 17S
- CVR (contraceptive vaginal ring)
- Cycle control,
 - ethinyl estradiol + levonorgestrel, 187
 - ethinyl estradiol + norethindrone acetate, 187
- Cyclofem®, acceptability, 383
- Depot-medroxyprogesterone acetate (DMPA),
 - discontinuation, 227
 - effect on bone mineral density, 25
 - effect on cervical epithelium, 363
 - effect on weight and blood pressure, 301
- Discontinuations, contraceptives, 227
- DMPA (depot-medroxyprogesterone acetate), 301
- Drug interactions, OC pill and antibiotics, 71
- Effectiveness, Yuzpe regimen of emergency contraception, 147
- Efficacy,
 - ethinyl estradiol + norethindrone acetate CVR, 311
 - Implanon, 167
 - Yuzpe regimen of emergency contraception, 147
- Elcometrine (ST-1435),
 - effect on breastfeeding, 115
 - implant contraceptive, 115
- Emergency contraception,
 - ethinyl estradiol + levonorgestrel, 147
 - level of knowledge, 253
 - risk of venous thromboembolism, 79
 - Yuzpe method, 147
- Endometrial microvascular density, Norplant implants users, 123
- Endometrium,
 - effect of Cu-Fix IUD
 - effect of levonorgestrel, 123
- Ethinyl estradiol, effect on daily sperm production (rat), 345
- Ethinyl estradiol + desogestrel,
 - ovarian activity during pill-free interval, 237
 - quality-of-life benefits, 287
 - user satisfaction, 287

- Ethinyl estradiol + gestodene, ovarian activity during pill-free interval, 237
- Ethinyl estradiol + levonorgestrel, effect on cycle control, 187
- Ethinyl estradiol + norethindrone acetate, clinical study, 161
- effect on cycle control, 187
- Ethinyl estradiol + norethindrone acetate CVR, clinical study, 305, 311
- Ethinyl estradiol + norgestimate, clinical study, 161
- Ethylene-vinyl-acetate copolymer, vaginal ring, 59
- Fertilin β protein, effect on fertilization (baboon), 131
- Fertilization, effect of fertilin β protein (baboon), 131
- Fluid medium, vaginal fluid simulant, 91
- Glucose metabolism, effect of testosterone enanthate (monkey), 333
- Health benefits, OC use, 29S
- Hemostatic variables, effects of OC regimens (study protocol), 377
- Hormone replacement therapy, bleeding patterns, 357
- Impact, introduction of the birth control pill, 11S
- Implanon® implant, clinical study, 167
- Implant contraceptive, elcometrine (ST-1435), 115
- etonogestrel, 167
- levonorgestrel, 31, 123, 245, 369, 389
- Implantation, effect of castor bean extract (rabbit), 401
- effect of ricin A-chain (rabbit), 401
- Injectable contraceptive, depot-medroxyprogesterone acetate, 25, 301, 363
- DMPA + estradiol cypionate, 383
- norethisterone enanthate + estradiol valerate, 383
- Interleukin-6 level, effect of progesterone-releasing IUD, 175
- Intrauterine device (IUD), Cu-Fix, 63
- discontinuations, 227
- progesterone-releasing, 175
- TCu 380A, 115, 233, 301
- user satisfaction
- Introduction of the birth control pill and its impact, 11S
- Irregular cycles, implications for fertility awareness methods, 271
- IUD candidates, STD risk assessment, 97
- Knowledge, attitudes and practice of emergency contraception, 253
- Knowledge sources, contraceptive methods, 257
- Levonorgestrel, effect on endometrium, 123
- effect on lipid metabolism, 31
- effect on ovarian function, 245
- Levonorgestrel implants, pop-out method of removal, 369
- Lipid metabolism, effect of copper IUDs, 31
- effect of levonorgestrel, 31
- Mechanism of action, copper IUDs, 67
- progesterone-releasing IUD, 175
- Medical abortion, methotrexate, 7, 395
- methotrexate + misoprostol, 7, 11, 265, 395
- mifepristone + misoprostol, 1, 107, 153
- misoprostol, 209, 219
- tamoxifen + misoprostol, 265
- Menstrual bleeding, hormone replacement therapy, 357
- OC use, 357
- relation to reproductive status, 357
- Menstrual cycles, incidence of irregular cycles, 271
- Mesigyna®, acceptability, 395
- Methotrexate, medical abortion, 7, 395
- Methotrexate + misoprostol, medical abortion, 7, 11, 265, 395
- Mifepristone + misoprostol, medical abortion, 1
- outcomes of procedure, 153
- side effects, 107
- Misoprostol, medical abortion, 209, 219, 395
- Natural contraceptive methods, effect of irregular cycles, 271
- Natural family planning, women's satisfaction, 277
- Nonmedicated vaginal ring, 59
- Norethisterone/metabolites, effect on uterine *c-fos* mRNA content (rat), 339
- effect on uterine progesterone receptor (rat), 339
- Normative reproductive indices, adult Sprague-Dawley rats, 203
- Norplant® implants, clinical evaluation, 389
- effect on endometrium, 123
- effect on lipid metabolism, 31
- onset of contraceptive effect, 245
- pop-out method of removal, 369
- OC (oral contraceptive)
- OC regimens, effects of hemostatic variables (study protocol), 377
- OC use, bleeding patterns, 357
- breast cancer risk, 25S
- cardiovascular risks, 21S
- clinician/patient interaction, 39S
- effect of smoking, 17
- health benefits, 29S

- Onset of contraceptive effectiveness, Norplant implants, 245
- Optical testing, condoms, 47
- Oral contraceptive (OC),
current use and attitudes, 17S
discontinuations, 227
ethinyl estradiol + desogestrel, 237, 287
ethinyl estradiol + gestodene, 237
ethinyl estradiol + levonorgestrel, 187
ethinyl estradiol + norethindrone acetate, 17, 161, 187
ethinyl estradiol + norgestimate, 161
interaction with antibiotics, 71
quality-of-life benefits, 35S
therapeutic uses, 35S
thrombophilic screening before use, 293
user satisfaction, 277
- Ovarian activity,
effect of Norplant implants, 245
pill-free period during OC use, 237
- Ovulation,
effect of castor bean extract (rabbit), 395
effect of ricin A-chain (rabbit), 401
- Pop-out method of removal, levonorgestrel implants, 369
- Postcoital contraceptive pills, risk of venous thromboembolism, 79
- Preferences, menstrual bleeding frequency, 357
- Prepill era, methods of contraception, 75
- Progesterone receptor, effect of
norethisterone/metabolites (rat), 339
- Progesterone-releasing IUD, possible mechanism of action, 175
- Prostacyclin levels, effect of ethinyl estradiol + norethindrone acetate, 17
- Prostate-specific antigen in vaginal fluid, biologic marker of condom failure, 195
- Quality-of-life benefits,
effect of ethinyl estradiol + desogestrel, 287
oral contraceptives, 35S
- Reactive nitrogen intermediates, effect of copper IUDs, 67
- Reactive oxygen intermediates, effect of copper IUDs, 67
- Removal of levonorgestrel implants, pop-out method, 369
- Reproductive indices (rat), 203
- Reproductive status, characteristics of menstrual bleeding, 357
- Ricin A-chain,
effect on implantation (rabbit), 401
effect of ricin A-chain (rabbit), 401
- Risks, OC use, 39S
- Satisfaction with birth control, 277
- Sexual function, climacteric women, 85
- Side effects,
mifepristone + misoprostol abortion, 107
surgical abortion, 107
use of ethinyl estradiol + norethindrone acetate
CVR, 311
- Smoking, effect of OC use, 17
- Sperm production,
effect of CDRI 84/35 (rat), 345
effect of estradiol (rat), 345
- Spermicidal activity, WHI-05, 319
- Sprague-Dawley rats, normative reproductive indices, 203
- STD (sexually transmitted diseases)
STD risk assessment, IUD candidates, 97
- Sterilization, women's satisfaction, 277
- Styrene maleic anhydride, effect on vas deferens (monkey) 137
- Suction curettage abortion, outcomes of procedure, 153
- Surgical abortion, side effects, 107
- Tamoxifen + misoprostol, medical abortion, 265
- TCu 380A,
effect on breastfeeding, 115
effect on weight and blood pressure, 301
long-term users, 223
- Therapeutic uses, oral contraceptives, 35S
- Thrombophilic screening, before OC treatment, 293
- Thromboxane A₂ levels, effect of ethinyl estradiol + norethindrone acetate, 17
- Triphasic ethinyl estradiol + norgestimate, clinical study, 161
- Tumor necrosis factor- α level, effect of
progesterone-releasing IUD, 175
- Vaginal fluid simulant, 91
- Vaginal ring, made of ethylene-vinyl-acetate copolymer, 59
- Vas deferens, effect of styrene maleic anhydride (monkey), 137
- Vas occlusion, styrene maleic anhydride (monkey), 137
- Vasectomy, risk of cardiovascular disease, 181
- Venous thromboembolism risk, postcoital contraceptive pill use, 79
- Weight,
effect of DMPA, 301
effect of TCu 380A, 301
- WHI-05,
spermicidal activity, 319
anti-HIV activity, 319
zidovudine derivative, 319
- Yuzpe regimen,
emergency contraception, 147
estimates of effectiveness, 147
- Zidovudine derivative, WHI-05, 389